Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OrigAMI-4 amivantamab study in head and neck squamous cell carcinoma
2023-508418-40-00Phase 2Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 11
01
Overview
Phase 2, open-label trial of amivantamab in head and neck squamous cell carcinoma (HNSCC) (7 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoints: Objective response rate, Dose-limiting toxicities and 2 more. Planned start Dec 2024; status: authorised.
02
Drugs
amivantamab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2023-508418-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508418-40-00.